tiprankstipranks
Advertisement
Advertisement

HCM Stock Latest News

Hutchmed price target lowered to $14 from $16 at Goldman Sachs
The FlyHutchmed price target lowered to $14 from $16 at Goldman Sachs
2d ago
HCM
Hutchmed’s HMPL‑760 Phase III Lymphoma Trial Moves Forward, Raising Long‑Term Stakes for HCM Investors
PremiumCompany Announcements
Hutchmed’s HMPL‑760 Phase III Lymphoma Trial Moves Forward, Raising Long‑Term Stakes for HCM Investors
4d ago
HCM
Hutchmed price target lowered to $17 from $20 at BofA
PremiumThe Fly
Hutchmed price target lowered to $17 from $20 at BofA
17d ago
HCM
Hutchmed announces China NMPA approval for Orpathys NDA
PremiumThe Fly
Hutchmed announces China NMPA approval for Orpathys NDA
23d ago
HCM
Hutchmed Moves HMPL-760 Forward With Food-Effect Study, Signaling Steady Pipeline Progress
PremiumCompany Announcements
Hutchmed Moves HMPL-760 Forward With Food-Effect Study, Signaling Steady Pipeline Progress
1M ago
HCM
Hutchmed upgraded to Equal Weight from Underweight at Morgan Stanley
PremiumThe FlyHutchmed upgraded to Equal Weight from Underweight at Morgan Stanley
2M ago
HCM
Hutchmed’s New HER2 Trial Adds Early Stage Upside to Its Oncology Pipeline
Premium
Company Announcements
Hutchmed’s New HER2 Trial Adds Early Stage Upside to Its Oncology Pipeline
2M ago
HCM
Hutchmed, Innovent jointly announce NMPA approval for Elunate/Tyvyt combination
Premium
The Fly
Hutchmed, Innovent jointly announce NMPA approval for Elunate/Tyvyt combination
2M ago
HCM
Hutchmed, Innovent Biologics announce China NMPA approval for NDA
PremiumThe Fly
Hutchmed, Innovent Biologics announce China NMPA approval for NDA
2M ago
HCM
Hutchmed says NDA for sovleplenib accepted in China
PremiumThe Fly
Hutchmed says NDA for sovleplenib accepted in China
3M ago
HCM
Hutchmed Expands Oncology Pipeline With New First‑in‑Human Solid Tumor Trial
PremiumCompany Announcements
Hutchmed Expands Oncology Pipeline With New First‑in‑Human Solid Tumor Trial
4M ago
HCM
Hutchmed price target lowered to $20 from $21 at BofA
PremiumThe Fly
Hutchmed price target lowered to $20 from $21 at BofA
5M ago
HCM
Hutchmed discontinues all active tazemetostat clinical trials
PremiumThe FlyHutchmed discontinues all active tazemetostat clinical trials
5M ago
HCM
Hutchmed price target lowered to $21 from $22 at BofA
Premium
The Fly
Hutchmed price target lowered to $21 from $22 at BofA
5M ago
HCM
Hutchmed reports publication of SACHI results in The Lancet
Premium
The Fly
Hutchmed reports publication of SACHI results in The Lancet
6M ago
AZN
HCM
Hutchmed says Phase III of ESLIM-02 trial met primary endpoint
PremiumThe Fly
Hutchmed says Phase III of ESLIM-02 trial met primary endpoint
7M ago
HCM
Hutchmed price target lowered to $22 from $25 at BofA
PremiumThe Fly
Hutchmed price target lowered to $22 from $25 at BofA
7M ago
HCM
Hutchmed initiates Phase III stage of Phase II/III trial
PremiumThe Fly
Hutchmed initiates Phase III stage of Phase II/III trial
7M ago
HCM
Hutchmed initiates Phase III stage of Phase II/III trial
PremiumThe Fly
Hutchmed initiates Phase III stage of Phase II/III trial
7M ago
HCM
Hutchmed announces savolitinib new drug application acceptance in China
PremiumThe FlyHutchmed announces savolitinib new drug application acceptance in China
7M ago
HCM
Hutchmed announces fanregratinib NDA acceptance in China with priority review
Premium
The Fly
Hutchmed announces fanregratinib NDA acceptance in China with priority review
7M ago
HCM
Hutchmed announces contract renewal with the China NHSA
Premium
The Fly
Hutchmed announces contract renewal with the China NHSA
8M ago
HCM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >